<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="hep41480-tbl-0001" xml:lang="en" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>Society‐Based Recommendations for Screening and Treatment for HCV Infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Society</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Year of Guideline/Guidance</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Screening</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Indication for Treatment</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="2" colspan="1">World Health Organization
     <xref rid="hep41480-bib-0078" ref-type="ref">78</xref>, 
     <xref rid="hep41480-bib-0079" ref-type="ref">79</xref>
    </td>
    <td align="left" rowspan="1" colspan="1">2017 (Screening)</td>
    <td align="left" rowspan="2" colspan="1">
     <p>Strategies for country‐specific testing policy: 
      <list list-type="bullet" id="hep41480-list-0001">
       <list-item>
        <p>High‐risk behaviors</p>
       </list-item>
       <list-item>
        <p>Past generalized exposures that have since been removed (“birth cohort” testing)</p>
       </list-item>
       <list-item>
        <p>Generalized population epidemic with high prevalence (whole population testing)</p>
       </list-item>
      </list>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">All individuals diagnosed with HCV infection who are 12 years of age or older, regardless of disease stage</td>
    <td align="left" rowspan="2" colspan="1">Strong recommendation, moderate quality of evidence</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">2018 (Treatment)</td>
    <td align="left" rowspan="1" colspan="1">Including MSM, PWID, and incarcerated individuals, with the exception of pregnant women</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">AASLD, Infectious Disease Society of America (IDSA)
     <xref rid="hep41480-bib-0013" ref-type="ref">13</xref>
    </td>
    <td align="left" rowspan="2" colspan="1">2019</td>
    <td align="left" rowspan="1" colspan="1">Risk behavior, risk exposure, or other conditions
     <xref ref-type="fn" rid="hep41480-note-0002">*</xref>
    </td>
    <td align="left" rowspan="2" colspan="1">All patients with chronic HCV, except for those with a short life expectancy who cannot be remediated by HCV therapy, liver transplantation, or another directed therapy</td>
    <td align="left" rowspan="2" colspan="1">Periodic repeat testing for persons with risk exposures, behaviors, conditions, or circumstances. Annual testing for PWID and MSM who are sexually active without protection</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">One‐time, routine opt‐out HCV testing in all patients 18+ years old. In those younger than 18 years, one‐time testing in those with risk exposures or behaviors</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">EASL
     <xref rid="hep41480-bib-0080" ref-type="ref">80</xref>
    </td>
    <td align="left" rowspan="2" colspan="1">2018</td>
    <td align="left" rowspan="1" colspan="1">Screening strategies for HCV infection should be defined according to the local epidemiology of HCV infection, ideally within the framework of national plans</td>
    <td align="left" rowspan="1" colspan="1">All treatment‐naïve and treatment‐experienced patients with HCV infection, who are willing to be treated and who have no contraindications
     <xref ref-type="fn" rid="hep41480-note-0003">†</xref> for treatment, should be treated
    </td>
    <td align="left" rowspan="2" colspan="1">Patients with decompensated (Child‐Pugh B or C) cirrhosis and an indication for liver transplantation with a MELD score ≥ 18‐20 should be transplanted first and treated after transplantation
     <xref ref-type="fn" rid="hep41480-note-0004">‡</xref>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Screening strategies may include screening of populations at risk for infection, birth cohort testing, and general population testing in areas of intermediate to high seroprevalence (≥ 2%‐5%)</td>
    <td align="left" rowspan="1" colspan="1">Treatment is generally not recommended in patients with limited life expectancy due to non‐live‐related comorbidities</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">U.S. Preventive Services Task Force
     <xref rid="hep41480-bib-0014" ref-type="ref">14</xref>
    </td>
    <td align="left" rowspan="2" colspan="1">2019 (in progress)</td>
    <td align="left" rowspan="2" colspan="1">Adults ages 18 to 79 years</td>
    <td align="left" rowspan="2" colspan="1">N/A</td>
    <td align="left" rowspan="1" colspan="1">Recommendation currently in draft form (public comment through 9/23/2019)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Update to previous recommendations to screen high‐risk and birth cohort
     <xref rid="hep41480-bib-0081" ref-type="ref">81</xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="hep41480-ntgp-0002">
  <fn id="hep41480-note-0002">
   <label>*</label>
   <p>Risk behaviors: injection drug use and intranasal illicit drug use. Risk exposures: hemodialysis, parenteral exposures, health care workers after exposure, children born to HCV‐infected women, prior recipients of transfusions or organ transplants, and ever incarcerated. Other conditions: HIV infection, sexually active about to start HIV postexposure prophylaxis, unexplained liver chemistry abnormalities, and solid organ donors.</p>
  </fn>
  <fn id="hep41480-note-0003">
   <label>
    <sup>†</sup>
   </label>
   <p>Use of certain cytochrome P450 inducing agents (carbamazepine, phenytoin) are contraindicated with all regimens. Regimens consisting of protease inhibitor must not be used in patients with Child‐Pugh B or C decompensated cirrhosis or in patients with previous episodes of decompensation. In patients with eGFR &lt; 30 mL/min/1.73 m
    <sup>2</sup>, sofosbuvir should only be used if no alternative treatment approved for use in severe renal impairment is available.
   </p>
  </fn>
  <fn id="hep41480-note-0004">
   <label>
    <sup>‡</sup>
   </label>
   <p>If the wait time on the liver transplant list is more than 6 months, then patient can be treated before transplantation, although the clinical benefit is not well established.</p>
  </fn>
  <fn id="hep41480-note-0005">
   <p>Abbreviations: eGFR, estimated glomerular filtration rate; MELD, Model for End‐Stage Liver Disease; MSM, men who have sex with men.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
